ALNY in “The Patent Cliff Sparks a Biotech Land Grab”
Alnylam Pharmaceuticals, Inc.
Alnylam's validated RNA-interference platform and growing commercial portfolio make its pipeline strategically scarce.
ALNY impact map — “The Patent Cliff Sparks a Biotech Land Grab”
How this story travels from the headline to ALNY’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading ALNY impact map…
Price history, marked with story events
Aug 31, 2026 – Oct 9, 2026 · 30 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
The Patent Cliff Sparks a Biotech Land Grab
Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
BULL side — Alnylam's validated RNA-interference platform and growing commercial portfolio make its pipeline strategically scarce.
Read the full The Patent Cliff Sparks a Biotech Land Grab storyBull side
1 story- Viewing
ALNY in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Alnylam's validated RNA-interference platform and growing commercial portfolio make its pipeline strategically scarce.
Bear side
1 story- America Imports the World's Drug Prices
ALNY in “America Imports the World's Drug Prices”
StableExposure: not rated yetUS reference pricing puts global blockbuster economics—and not just American list prices—under pressure.
Alnylam's high-priced RNA-interference medicines rely on orphan-drug economics that could be diluted if US payers import lower overseas benchmarks.